CompletedPhase 1NCT02082860
Phase I Gene Therapy Clinical Trial Using the Vector rAAV2/5-PBGD for the Treatment of Acute Intermittent Porphyria
Studying Disorder of porphyrin and heme metabolism
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Digna Biotech S.L.
- Principal Investigator
- Juan Ruiz, MDDigna Biotech S.L.
- Intervention
- rAAV2/5-PBGD vector dosage 1(genetic)
- Enrollment
- 8 enrolled
- Eligibility
- 18-64 years · All sexes
- Timeline
- 2012 – 2014
Study locations (2)
- 12 Octubre Hospital, Madrid, Madrid, Spain
- Clinica Universidad de Navarra, Pamplona, Navarre, Spain
Collaborators
Porphyria Centre Sweden · University of Navarra · UniQure N.V. · Nationales Centrum für Tumorerkrankungen
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT02082860 on ClinicalTrials.govOther trials for Disorder of porphyrin and heme metabolism
Additional recruiting or active studies for the same condition.
- ACTIVE NOT RECRUITINGPHASE3NCT06910358Study of Bitopertin in Participants With EPP or XLP (APOLLO)Disc Medicine, Inc
- ENROLLING BY INVITATIONPHASE2NCT06971900GATEWAY: A Phase 2a Study of PORT-77 in Adults With Erythropoietic ProtoporphyriaPortal Therapeutics, Inc.
- ACTIVE NOT RECRUITINGNCT02935400Acute Porphyria Biomarkers for Disease ActivityThe University of Texas Medical Branch, Galveston
- ACTIVE NOT RECRUITINGNCT01617642Dental Health, Diet, Inflammation and Biomarkers in Patients With Acute Intermittent Porphyria(AIP)Nordlandssykehuset HF
See all trials for Disorder of porphyrin and heme metabolism →